Evidence map›Paper›PMID 42491848›Full record

ArticleiScience2026

Reversal of T cell exhaustion enables cancer vaccine efficacy in

Laurent Beziaud, Aspram Minasyan, Cheryl L-L Chiang, Rania M Soukarieh, Matilde M Coppi, Raphaël Rovelli, Jonathan Thevenet, Stephanie Tissot, Denarda Dangaj-Laniti, Lana E Kandalaft

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laurent BeziaudDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Aspram MinasyanDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Cheryl L-L ChiangDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Rania M SoukariehDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Matilde M CoppiDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Raphaël RovelliDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Jonathan ThevenetCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Stephanie TissotCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Denarda Dangaj-LanitiDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Lana E KandalaftDepartment of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Agora Cancer Research Center, Swiss Medical Network, Genolier Innovation Network, Genolier Clinic, Genolier, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRCA mutations in ovarian cancer (OC) are associated with increased tumor-infiltrating lymphocytes and inflammatory features, yet immunotherapy for OC has shown limited efficacy. Using the ID8 mouse model, we discovered that

Indexed as

BRCA1 mutationcancer vaccineimmune checkpoint blockadeovarian cancerPARP inhibitionT cell exhaustion

Identifiers

PMID42491848
PMCPMC13378375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.